NYHA | |||||||
---|---|---|---|---|---|---|---|
ACHD group | n | Age (years) | Male gender n (%) | I (%) | II (%) | ≥III (%) | Follow-up (years) |
Aortic coarctation | 266 | 29.6 (21.7 to 41.0) | 150 (56.4%) | 85.60 | 13.40 | 1.00 | 6.7 (3.5 to 10.7) |
Atrial septal defect | 479 | 44.0 (31.1 to 58.6) | 181 (37.8%) | 63.00 | 33.00 | 4.00 | 5.9 (4.0 to 9.0) |
Atrioventricular septal defect | 113 | 37.5 (25.9 to 49.0) | 47 (41.6%) | 59.80 | 36.10 | 4.10 | 6.8 (3.7 to 9.7) |
CCTGA | 63 | 35.7 (24.6 to 45.2) | 32 (50.8%) | 43.80 | 35.40 | 20.80 | 5.6 (2.7 to 8.8) |
Complex ACHD | 172 | 29.0 (22.5 to 37.6) | 83 (48.3%) | 29.00 | 60.70 | 10.30 | 5.5 (2.9 to 9.7) |
Ebstein anomaly | 86 | 40.2 (29.3 to 49.9) | 42 (48.8%) | 48.40 | 40.30 | 11.30 | 5.1 (3.2 to 7.6) |
Eisenmenger syndrome | 259 | 33.6 (25.7 to 42.4) | 96 (37.1%) | 4.80 | 57.20 | 38.00 | 6.1 (3.2 to 9.0) |
Fontan palliation | 110 | 24.1 (20.0 to 31.9) | 55 (50.0%) | 44.10 | 52.70 | 3.20 | 6.7 (3.8 to 10.8) |
Other ACHD | 261 | 29.7 (21.2 to 40.8) | 148 (56.7%) | 72.40 | 23.10 | 4.50 | 4.8 (2.9 to 9.0) |
Postatrial switch for TGA | 85 | 28.9 (22.9 to 32.6) | 43 (50.6%) | 64.80 | 32.40 | 2.80 | 6.4 (3.5 to 12.1) |
Tetralogy of Fallot | 474 | 30.8 (22.2 to 40.8) | 263 (55.5%) | 62.60 | 34.40 | 3.00 | 5.4 (3.3 to 9.9) |
Valve/outflow disease | 518 | 36.4 (25.1 to 48.3) | 305 (58.9%) | 67.60 | 26.80 | 5.60 | 5.3 (3.4 to 9.3) |
Total | 2886 | 33.3 (23.6 to 44.7) | 1445 (50.1%) | 57.10 | 34.90 | 8.00 | 5.7 (3.3 to 9.6) |
The ‘Complex ACHD’ subgroup includes single-ventricle physiology patients without evidence of pulmonary hypertension. Patients classified as ‘other ACHD’ are patients with restrictive ventricular septal defects, repaired persistent ductus arteriosus, Marfan syndrome or patients with TGA after arterial switch.
ACHD, adult congenital heart disease; CCTGA, congenitally corrected transposition of the great arteries; NYHA, New York Heart Association; TGA, transposition of the great arteries.